Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated:  9/28/2017
University of Colorado Cancer Center
mi
from
Aurora, CO
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated: 9/28/2017
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated:  9/28/2017
Northwestern University
mi
from
Chicago, IL
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated: 9/28/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated:  9/28/2017
The Bays St Mary's Hospital
mi
from
London,
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Status: Enrolling
Updated: 9/28/2017
The Bays St Mary's Hospital
mi
from
London,
Click here to add this to my saved trials
Study of Gut Microbiome and Colorectal Tumors
The Gut Microbiota in Conventional and Serrated Precursors of Colorectal Cancer
Status: Enrolling
Updated:  9/28/2017
New York University School of Medicine
mi
from
New York, NY
Study of Gut Microbiome and Colorectal Tumors
The Gut Microbiota in Conventional and Serrated Precursors of Colorectal Cancer
Status: Enrolling
Updated: 9/28/2017
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy
Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy in Early Stage Breast Cancer After Breast-Conserving Surgery
Status: Enrolling
Updated:  9/28/2017
University of Michigan
mi
from
Ann Arbor, MI
Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy
Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy in Early Stage Breast Cancer After Breast-Conserving Surgery
Status: Enrolling
Updated: 9/28/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Phase 2 Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Status: Enrolling
Updated:  9/29/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Phase 2 Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Status: Enrolling
Updated: 9/29/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  9/29/2017
University of California San Diego - Moores Cancer Center Dept Onc
mi
from
La Jolla, CA
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 9/29/2017
University of California San Diego - Moores Cancer Center Dept Onc
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  9/29/2017
H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC
mi
from
Tampa, FL
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 9/29/2017
H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  9/29/2017
Northwestern Memorial Hospital
mi
from
Chicago, IL
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 9/29/2017
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  9/29/2017
Massachusetts General Hospital CCPO
mi
from
Boston, MA
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 9/29/2017
Massachusetts General Hospital CCPO
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  9/29/2017
University of Texas/MD Anderson Cancer Center Dept of Onc.
mi
from
Houston, TX
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 9/29/2017
University of Texas/MD Anderson Cancer Center Dept of Onc.
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  9/29/2017
University of Utah / Huntsman Cancer Institute Huntsman 3
mi
from
Salt Lake City, UT
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 9/29/2017
University of Utah / Huntsman Cancer Institute Huntsman 3
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  9/29/2017
Array BioPharma Investigative Site
mi
from
Parkville,
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 9/29/2017
Array BioPharma Investigative Site
mi
from
Parkville,
Click here to add this to my saved trials
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  9/29/2017
Memorial Sloan Kettering Cancer Center Onc Dept.
mi
from
New York, NY
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 9/29/2017
Memorial Sloan Kettering Cancer Center Onc Dept.
mi
from
New York, NY
Click here to add this to my saved trials
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  9/29/2017
Montefiore Medical Center SC
mi
from
The Bronx, NY
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 9/29/2017
Montefiore Medical Center SC
mi
from
The Bronx, NY
Click here to add this to my saved trials
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
A Phase 1, Open-Label, Randomized, Parallel Group Study Evaluating the Pharmacokinetics of FTD as a Component of TAS-102 Compared With FTD Alone
Status: Enrolling
Updated:  9/29/2017
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
A Phase 1, Open-Label, Randomized, Parallel Group Study Evaluating the Pharmacokinetics of FTD as a Component of TAS-102 Compared With FTD Alone
Status: Enrolling
Updated: 9/29/2017
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
DC Vaccine for Patients With Ductal Carcinoma In Situ
A Randomized Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With DCIS
Status: Enrolling
Updated:  9/29/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
DC Vaccine for Patients With Ductal Carcinoma In Situ
A Randomized Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With DCIS
Status: Enrolling
Updated: 9/29/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
Status: Enrolling
Updated:  9/29/2017
Shadyside Urology
mi
from
Pittsburgh, PA
Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
Status: Enrolling
Updated: 9/29/2017
Shadyside Urology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response
Status: Enrolling
Updated:  10/2/2017
University of Maryland, Baltimore
mi
from
Baltimore, MD
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response
Status: Enrolling
Updated: 10/2/2017
University of Maryland, Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
A Phase 1 Study of Copanlisib(Phosphatidylinositol-3 Kinase Inhibitor) in Combination With Gemcitabine (Treatment A) or Cisplatin Plus Gemcitabine (Treatment B) in Subjects With Advanced Solid Malignancy
Status: Enrolling
Updated:  10/2/2017
Clinical Research Facility
mi
from
Tampa, FL
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
A Phase 1 Study of Copanlisib(Phosphatidylinositol-3 Kinase Inhibitor) in Combination With Gemcitabine (Treatment A) or Cisplatin Plus Gemcitabine (Treatment B) in Subjects With Advanced Solid Malignancy
Status: Enrolling
Updated: 10/2/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
A Phase 1 Study of Copanlisib(Phosphatidylinositol-3 Kinase Inhibitor) in Combination With Gemcitabine (Treatment A) or Cisplatin Plus Gemcitabine (Treatment B) in Subjects With Advanced Solid Malignancy
Status: Enrolling
Updated:  10/2/2017
Clinical Research Facility
mi
from
Rochester, MN
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
A Phase 1 Study of Copanlisib(Phosphatidylinositol-3 Kinase Inhibitor) in Combination With Gemcitabine (Treatment A) or Cisplatin Plus Gemcitabine (Treatment B) in Subjects With Advanced Solid Malignancy
Status: Enrolling
Updated: 10/2/2017
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
A Phase 1 Study of Copanlisib(Phosphatidylinositol-3 Kinase Inhibitor) in Combination With Gemcitabine (Treatment A) or Cisplatin Plus Gemcitabine (Treatment B) in Subjects With Advanced Solid Malignancy
Status: Enrolling
Updated:  10/2/2017
Clinical Research Facility
mi
from
Chapel Hill, NC
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
A Phase 1 Study of Copanlisib(Phosphatidylinositol-3 Kinase Inhibitor) in Combination With Gemcitabine (Treatment A) or Cisplatin Plus Gemcitabine (Treatment B) in Subjects With Advanced Solid Malignancy
Status: Enrolling
Updated: 10/2/2017
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
Status: Enrolling
Updated:  10/2/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/2/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
Status: Enrolling
Updated:  10/2/2017
Dana-Farber Cancer Inst
mi
from
Boston, MA
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/2/2017
Dana-Farber Cancer Inst
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
Status: Enrolling
Updated:  10/2/2017
University of Oklahoma
mi
from
Oklahoma City, OK
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/2/2017
University of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
Status: Enrolling
Updated:  10/2/2017
Sarah Cannon Research Inst
mi
from
Nashville, TN
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/2/2017
Sarah Cannon Research Inst
mi
from
Nashville, TN
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Comprehensive Cancer Institute
mi
from
Huntsville, AL
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Comprehensive Cancer Institute
mi
from
Huntsville, AL
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Huntsville Hospital
mi
from
Huntsville, AL
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Huntsville Hospital
mi
from
Huntsville, AL
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
MBCCOP - Gulf Coast
mi
from
Mobile, AL
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
MBCCOP - Gulf Coast
mi
from
Mobile, AL
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Montgomery Cancer Center
mi
from
Montgomery, AL
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Montgomery Cancer Center
mi
from
Montgomery, AL
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
DCH Cancer Treatment Center
mi
from
Tuscaloosa, AL
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
DCH Cancer Treatment Center
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Foundation for Cancer Research and Education
mi
from
Phoenix, AZ
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Foundation for Cancer Research and Education
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Mount Diablo Medical Center
mi
from
Concord, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Mount Diablo Medical Center
mi
from
Concord, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
California Cancer Center
mi
from
Fresno, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
California Cancer Center
mi
from
Fresno, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Saint Agnes Cancer Center
mi
from
Fresno, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Saint Agnes Cancer Center
mi
from
Fresno, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Sutter Health Western Division Cancer Research Group
mi
from
Greenbrae, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Sutter Health Western Division Cancer Research Group
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Loma Linda University Cancer Institute at Loma Linda University Medical Center
mi
from
Loma Linda, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Loma Linda University Cancer Institute at Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Veterans Affairs Medical Center - Long Beach
mi
from
Long Beach, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Veterans Affairs Medical Center - Long Beach
mi
from
Long Beach, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
CCOP - Bay Area Tumor Institute
mi
from
Oakland, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
CCOP - Bay Area Tumor Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Huntington Cancer Center at Huntington Hospital
mi
from
Pasadena, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Huntington Cancer Center at Huntington Hospital
mi
from
Pasadena, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Robert and Beverly Lewis Family Cancer Care Center
mi
from
Pomona, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Robert and Beverly Lewis Family Cancer Care Center
mi
from
Pomona, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Radiation Oncology Center - Sacramento
mi
from
Sacramento, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Radiation Oncology Center - Sacramento
mi
from
Sacramento, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Radiation Medical Group, Incorporated
mi
from
San Diego, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Radiation Medical Group, Incorporated
mi
from
San Diego, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Naval Medical Center - San Diego
mi
from
San Diego, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Naval Medical Center - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials